Clinical trial • Phase III • Oncology|Other
Clinical trial in Cancer
Phase III trial for Cancer. 120 participants.
Overview
- Trial Therapeutic Area
- Oncology|Other
- Trial Disease
- Cancer
- Trial Stage
- Phase III
- Drug Modality
- Radiopharmaceutical
Key dates
- Initial CTIS Submission Date
- 27-05-2024
- First CTIS Authorization Date
- 16-09-2024
Trial design
Phase III trial across 1 site in Netherlands.
- Target Sample Size
- 120
Recruitment
- Planned Sample Size
- 120
- Recruitment Window Months
- 36
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 120
Netherlands
- Earliest CTIS Part Ii Submission Date
- 01-08-2024
- Latest Decision Or Authorization Date
- 16-06-2025
- Processing Time Days
- 319
- Number Of Sites
- 1
- Number Of Participants
- 120
Sites
- Site Name
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Department Name
- Nuclear medicine
- Principal Investigator Name
- B.J. de Wit-van der Veen
- Principal Investigator Email
- l.vd.veen@nki.nl
- Contact Person Name
- B.J. de Wit-van der Veen
- Contact Person Email
- l.vd.veen@nki.nl
- Number Of Participants
- 120
Sponsor
Primary sponsor
- Full Name
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.